Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread)--and warning on Viagra, Cialis, and Levitra.On March 19, 2004 the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. notified the public of new prescribing information and precautions precautions Infectious disease The constellation of activities intended to minimize exposure to an infectious agent; precautions imply that the isolation of an infected Pt is optional, but not mandatory. for atazanavir (brand name Reyataz), if taken in combination with tenofovir tenofovir /te·no·fo·vir/ (te-no´fo-vir?) an antiretroviral agent that inhibits reverse transcriptase; used as t. disoproxil fumarate in the treatment of HIV-1 (human immunodeficiency virus-1) infection. (Viread)--and warned of risks with Viagra or similar drugs. If atazanavir is taken with tenofovir, the blood level of atazanavir is decreased. Therefore it is now recommended that a small dose of ritonavir ritonavir /ri·to·na·vir/ (ri-to´nah-vir) an HIV protease inhibitor used in treatment of HIV infection and AIDS. ri·ton·a·vir n. be taken in addition, to raise the blood level of atazanavir to compensate. All three drugs are taken together once per day, with food. Also, Reyataz increases the blood level of Viread, which could increase its side effects Side effects Effects of a proposed project on other parts of the firm. . As a precaution, patients combining the drugs should be monitored for tenofovir side effects. The new Patient Information flyer also warns that if atazanavir is combined with Viagra, Cialis, or Levitra, it could increase the risk of serious side effects of those drugs. Patients are advised not to combine atazanavir with any of these drugs unless their doctor tells them it is OK. For more information see the new prescribing information for atazanavir, which will be posted at http://www.reyataz.com (we did not find it on the site on April 14). Also see the Patient Information flyer, which may be posted at the end of the prescribing information. |
|
||||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion